RVTY at a glance
Revvity (RVTY, SEC CIK 31791) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), Revvity (RVTY) reported revenue of $2.9 billion (up 3.7% from FY2024) and net income of $241.2 million. Diluted EPS was $2.07.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Revvity (RVTY) shares worth $5.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Gonzales Anita on October 1, 2026 of 84 shares at $155.48 per share.
- In the last 90 days, RVTY insiders reported 0 open-market purchases ($0) and 4 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.9B
- +3.7% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$1.3M
- 13F holders
- 34 funds
- $5.0B · +3 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Management Discussion & Analysis
- Revenue $2,856.1M in FY2025, up $101.1M (+4%) YoY; Diagnostics +5% ($68.5M), Life Sciences +2% ($32.5M)
- Gross margin 54.8% vs 55.8%; operating margin decreased 10 bps; SG&A ratio 34.7% vs 36.1%
- Best segment: Diagnostics revenue +5% to $1,424.9M; worst: Life Sciences margin 32.0% vs 33.4% (-139 bps), Diagnostics margin 24.2% vs 26.1% (-194 bps)
- Operating cash flow $589.0M vs $665.0M; buybacks $820.8M; capex $73.5M; dividends $32.8M
- Key risks: tariff impact ~$20M net on gross margin; Life Sciences Solutions goodwill ($4.5B) fair value only 10–20% above carrying value; capex planned higher in FY2026
Business Overview
- Health science solutions provider across two segments (Life Sciences and Diagnostics), serving drug discovery through clinical diagnostics in 160+ countries
- Notable new products in FY2025: Phenologic.AI™ deep-learning imaging module, EnVision Nexus® plate reader, NeoLSD™ 7 Plex MS/MS kit (first IVD for 7 lysosomal disorders from single blood spot), and T-SPOT.Flex™ customizable ELISPOT kit
- AI integration accelerated across portfolio: Pin-point® base editing expanded with Profluent AI-enhanced adenine deaminase editors; EUROPattern™ Classifier 2.4 AI-enhanced IFA software; Living Image™ Synergy AI multimodal imaging platform
- ~11,000 employees globally as of Dec 28, 2025; ~80% based outside the US; ~4,000 covered by labor union/works council agreements
- Great Place to Work certifications achieved across India, China, Poland, US, and Brazil (Euroimmun) in 2025, with improved US scores YoY: notable cultural milestone for a company mid-transformation from PerkinElmer rebrand
Risk Factors
- Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S.
- U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments
- Single/limited-source suppliers for critical raw materials with multi-year contracts carrying no minimum purchase requirements, creating supply disruption risk
- $9.0B net intangible assets on balance sheet as of December 28, 2025: impairment risk if Life Sciences or Diagnostics segments underperform
- Substantial debt across multiple tranches (2026–2051 Notes) with covenants restricting dividends, asset sales, and M&A; loss of investment-grade rating triggers higher costs
AI summary of the RVTY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 5, 2026
Management Discussion & Analysis
- Revenue $729.7M, up $9.4M or 1% YoY
- Diagnostics strongest segment, revenue $371.0M, up $16.6M or 5% YoY
- Life Sciences weakest segment, revenue $358.7M, down $7.2M or 2% YoY
- Gross margin 57.1% vs 54.5%; operating margin 12.2% vs 12.6% YoY
- Cash $1,022.9M; operating cash flow $317.8M for six months, up $49.4M YoY
- Outlook: internal operations expected to fund expenses, acquisitions, debt service and dividends for at least 12 months; tariff-recovery timing remains uncertain
Risk Factors
- Government funding and regulatory uncertainty: recently proposed U.S. changes have made customers more cautious on instrumentation and consumable purchases
- AI deployment: evolving cybersecurity, intellectual-property, privacy, and data-protection rules create potential liability and regulatory action
- Near-term demand: pharmaceutical, biotechnology, and research customers may delay purchases amid funding uncertainty and restricted capital spending
- Supply-chain disruption: limited or single-source suppliers could cause higher prices, quality declines, or delivery delays
- Intangible-asset impairment: $8.8 billion of net intangible assets exposed to adverse valuation changes or slower Life Sciences and Diagnostics growth
AI summary of the RVTY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Filing contains only the signature block for REVVITY’s August 4, 2026 report
- No earnings figures, operating results, or financial-condition information included in the provided text
Item 8.01: Other Events
- Planned sale of substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
- Definitive agreement signed July 31, 2026, with closing expected by end of 2027
Item 2.02: Results of Operations and Financial Condition
- Filing contains only the signature page for REVVITY’s May 5, 2026 report
- No earnings figures, reporting-period results, or operating metrics included in the provided text
Item 8.01: Other Events
- Probable sale of China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
- Management expects transaction closing in 2027, creating timing uncertainty for proceeds and portfolio impact
Item 5.07: Submission of Matters to a Vote of Security Holders
- All ten director nominees reelected for one-year terms, preserving board continuity
- Deloitte & Touche ratified as independent auditor, with 102,992,151 votes for
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Shareholders approved a 25% ownership threshold to call special meetings, effective April 28, 2026
- Lower threshold increases shareholder ability to challenge management or seek governance changes
AI summaries of RVTY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RVTY
Don't miss the next RVTY filing
- Alerts as it files. A push when RVTY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RVTY, by share count.
- Ask anything. An AI agent that reads every RVTY filing and answers with sources.
RVTY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gonzales Anita | Sell | Oct 1, 2026 | 84 | $155.48 |
| Krakowiak Maxwell | Sell | Sep 21, 2026 | 1,631 | $144.53 |
| Vohra Tajinder S | Sell | Sep 16, 2026 | 7,330 | $140.88 |
| MICHAS ALEXIS P | G | Aug 25, 2026 | 285 | - |
| Goldberg Joel S | G | Aug 14, 2026 | 27,785 | - |
| Goldberg Joel S | G | Aug 14, 2026 | 27,785 | - |
| Singh Prahlad R. | G | Aug 13, 2026 | 59,650 | - |
| Singh Prahlad R. | G | Aug 13, 2026 | 7,636 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.8B | $2.8B | $2.9B |
| Operating Income | $300.6M | $346.7M | $356.6M |
| Net Income | - | $270.4M | $241.2M |
| Op. Margin | 10.9% | 12.6% | 12.5% |
| Net Margin | - | 9.8% | 8.4% |
| Balance Sheet | |||
| Total Assets | - | $12.4B | $12.2B |
| Equity | $7.9B | $7.7B | $7.3B |
| ROE | - | 3.5% | 3.3% |
| Per Share | |||
| EPS | - | $2.20 | $2.07 |
| Cash Flow | |||
| Operating CF | - | $628.3M | $582.9M |
| CapEx | $81.4M | $86.6M | $73.5M |
Source: XBRL data in Revvity (RVTY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RVTY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $5.00B |
| Q1 2026 | 31 | $4.10B |
| Q4 2025 | 32 | $4.49B |
| Q3 2025 | 32 | $4.20B |
| Q2 2025 | 31 | $4.45B |
| Q1 2025 | 27 | $3.18B |
| Q4 2024 | 23 | $2.83B |
| Q3 2024 | 20 | $1.33B |
- Citadel Advisors LLC+1.39M (+2226%)
- Dimensional Fund Advisors+510.7K (+18%)
- Goldman Sachs Group+419.1K (+87%)
- BlackRock+408.0K (+6%)
- FMR LLC (Fidelity)+116.3K (+33%)
- T. Rowe Price Group−4.56M (-45%)
- Invesco Ltd−293.1K (-11%)
- Morgan Stanley−108.2K (-4%)
- Bank of America Corp−97.5K (-11%)
- Vanguard Portfolio Management LLC−42.7K (-1%)
- Millennium Management+75.2K
- Allstate+12.8K
- Two Sigma Investments+11.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 230 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RVTY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jul 5, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 10-Q | May 12, 2026 | Apr 5, 2026 | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 1, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
RVTY SEC filings: frequently asked questions
Are RVTY insiders buying or selling?
In the last 90 days, Revvity (RVTY) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $1.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RVTY stock?
As of June 30, 2026, the largest Revvity (RVTY) holders among the 13F filers tracked by SignalX were BlackRock ($852.1 million), Vanguard Capital Management LLC ($812.3 million), T. Rowe Price Group ($615.4 million), Vanguard Portfolio Management LLC ($530.8 million), State Street Corp ($483.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RVTY's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), Revvity (RVTY) reported revenue of $2.9 billion (up 3.7% from FY2024) and net income of $241.2 million. Diluted EPS was $2.07. The figures come from the XBRL data in the 10-K.
What are the main risks in RVTY's latest 10-K?
In the 10-K filed February 24, 2026, Revvity (RVTY) flagged: Tariffs imposed in fiscal year 2025 increased cost of revenue by ~$25M and reduced gross margin by ~$20M, primarily on European-manufactured products sold in U.S. U.S. government funding uncertainty causing cautious customer spending on instrumentation and consumables across pharma, biotech, and academic segments. (AI summary of the Risk Factors section.)
What did RVTY report in its latest 8-K?
Revvity (RVTY) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Filing contains only the signature block for REVVITY’s August 4, 2026 report.
What are the latest RVTY SEC filings?
Revvity (RVTY) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on October 2, 2026.
What is RVTY's SEC CIK number?
Revvity (RVTY)'s SEC Central Index Key (CIK) is 31791. EDGAR lists every RVTY filing under that number.
Ask anything about RVTY
The research agent reads RVTY's filings, financials, insider trades and 13F holders, then answers with sources.